Time-dependent differences in vancomycin sensitivity of macrophages underlie vancomycin-induced acute kidney injury.

kidney disease macrophages pharmacodynamics renal toxicity

Journal

The Journal of pharmacology and experimental therapeutics
ISSN: 1521-0103
Titre abrégé: J Pharmacol Exp Ther
Pays: United States
ID NLM: 0376362

Informations de publication

Date de publication:
28 Nov 2023
Historique:
accepted: 07 11 2023
received: 04 08 2023
revised: 21 10 2023
medline: 5 12 2023
pubmed: 5 12 2023
entrez: 5 12 2023
Statut: aheadofprint

Résumé

Although vancomycin (VCM)-frequently used to treat drug-resistant bacterial infections-often induces acute kidney injury (AKI), discontinuation of the drug is the only effective treatment; therefore, analysis of effective avoidance methods is urgently needed. Here, we report the differences in the induction of AKI by VCM in 1/2-nephrectomized mice depending on the time of administration. Despite the lack of difference in the accumulation of VCM in the kidney between the light (ZT2) and dark phases (ZT14), the expression of AKI markers due to VCM was observed only in the ZT2 treatment. Genomic analysis of the kidney suggested that the time of administration was involved in VCM-induced changes in monocyte and macrophage activity, and VCM had time-dependent effects on renal macrophage abundance, ATP activity, and IL-1β expression. Furthermore, the depletion of macrophages with clodronate abolished the induction of IL-1β and AKI marker expression by VCM administration at ZT2. This study provides evidence of the need for time-dependent pharmacodynamic considerations in the prevention of VCM-induced AKI as well as the potential for macrophage-targeted AKI therapy.

Identifiants

pubmed: 38050132
pii: jpet.123.001864
doi: 10.1124/jpet.123.001864
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023 American Society for Pharmacology and Experimental Therapeutics.

Auteurs

Yuya Yoshida (Y)

Faculty of Pharmaceutical Sciences, Department of Clinical Pharmacokinetics, Kyushu University, Japan.

Taiki Fukuda (T)

Faculty of Pharmaceutical Sciences, Department of Clinical Pharmacokinetics, Kyushu University, Japan.

Kohei Fukuoka (K)

Faculty of Pharmaceutical Sciences, Department of Pharmaceutics, Kyushu University, Japan.

Toshitaka Nagayama (T)

Faculty of Pharmaceutical Sciences, Department of Pharmaceutics, Kyushu University, Japan.

Tomohito Tanihara (T)

Faculty of Pharmaceutical Sciences, Department of Clinical Pharmacokinetics, Kyushu University, Japan.

Naoki Nishikawa (N)

Faculty of Pharmaceutical Sciences, Department of Clinical Pharmacokinetics, Kyushu University, Japan.

Kaita Otsuki (K)

Faculty of Pharmaceutical Sciences, Department of Clinical Pharmacokinetics, Kyushu University, Japan.

Yuma Terada (Y)

Faculty of Pharmaceutical Sciences, Department of Clinical Pharmacokinetics, Kyushu University, Japan.

Kengo Hamamura (K)

Faculty of Pharmaceutical Sciences, Department of Clinical Pharmacokinetics, Kyushu University, Japan.

Kosuke Oyama (K)

Faculty of Pharmaceutical Sciences, Department of Pharmaceutics, Kyushu University, Japan.

Akito Tsuruta (A)

Department of Pharmaceutics, Kyushu University, Japan.

Kota Mayanagi (K)

Faculty of Pharmaceutical Sciences, Department of Drug Discovery Structural Biology, Kyushu University, Japan.

Satoru Koyanagi (S)

Medico-pharmaceutical Sciences, Kyushu University, Japan.

Naoya Matsunaga (N)

Department of Pharmaceutics, kyushu university, Japan ohdo@phar.kyushu-u.ac.jp.

Shigehiro Ohdo (S)

Department of Medico-Pharmaceutical Sciences, Kyushu University, Japan ohdo@phar.kyushu-u.ac.jp.

Classifications MeSH